The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy.
Trends Cell Biol
; 29(1): 31-43, 2019 01.
Article
em En
| MEDLINE
| ID: mdl-30153961
During cancer initiation and progression, the somatic epigenome is broadly reprogrammed. This reprogramming can be a consequence of several processes, including altered transcriptional profiles and mutations. In addition, immune cells infiltrating the tumor microenvironment display a reprogrammed epigenome. For instance, tumor infiltrating T cells frequently exhibit an exhausted phenotype characterized by aberrant DNA methylation. Moreover, these aberrant epigenomes of cancer cells and infiltrating immune cells may represent a cancer vulnerability. Accumulating evidence supports the potential of using epigenetic therapy to not only reactivate silenced genes in cancer cells, but to also increase antitumor immunogenicity, by reactivation of endogenous retroviruses, to increase tumor immune-infiltration, and to reinvigorate T cell exhaustion. These findings highlight the potential synergies between epigenetic therapies and immunotherapy.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Epigênese Genética
/
Imunoterapia
/
Neoplasias
Limite:
Humans
Idioma:
En
Revista:
Trends Cell Biol
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Canadá